HOME >> BIOLOGY >> NEWS
New strategy rapidly identifies cancer targets

In a step toward personalized medicine, Howard Hughes Medical Institute investigator Brian J. Druker and colleagues have developed a new technique to identify previously unknown genetic mutations that can trigger cancerous growth. By analyzing the proteins instead of the genes inside acute myeloid leukemia (AML) cells, the researchers have dramatically reduced the time it takes to zero in on molecular abnormalities that might be vulnerable to specific drug treatments.

"This approach gives us a way to figure out what's driving the growth of a cancer in an individual patient and ultimately match that patient with the right drug," said Druker, who is based at the Oregon Health & Science University in Portland. Druker's team collaborated on the research, which was published in the July 17, 2006, issue of the journal Cancer Cell, with scientists in the lab of D. Gary Gilliland, an HHMI investigator at Brigham and Women's Hospital, as well as researchers at the Portland VA Medical Center, Cell Signaling Technology, the University of Chicago, and Yale University.

Traditionally, cancer-gene hunters have scanned the genome looking for mutations that trigger out-of-control cell growth. Druker tried this approach, but found it wanting. "We were doing some high-throughput DNA sequencing, and we weren't really finding much," he said.

Instead, the team added tools from the burgeoning field of proteomics, the study of proteins. "We decided this more functional assay would get us to the disease-causing genes more rapidly," said Druker, who has been studying a group of cell-signaling proteins called tyrosine kinases for 20 years.

Tyrosine kinases play a key role in many cancers. In healthy cells, they help form a chain of signals that prompt normal cell growth and division. Sometimes, though, a tyrosine kinase gets stuck in an "on" position, driving out-of-control cell division and, ultimately, cancer. This potentially devastating kinase act
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
16-Jul-2006


Page: 1 2 3

Related biology news :

1. New strategy for treating allergic disorders
2. Does EPA have an adequate strategy to oversee nanotechnologies?
3. High blood pressure medication strategy proves effective in Hispanic women
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Scientists identify new strategy for preventing acute and chronic brain disease
6. International risk research strategy and funding needed for nanotech safety
7. Study shows metabolic strategy of stressed cell
8. Trojan horse strategy defeats drug-resistant bacteria
9. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
10. Drug strategy makes cancer genes get lost in translation
11. Researchers develop new strategy for the treatment of CML

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:3/1/2017)... -- Aware, Inc. (NASDAQ: AWRE), a leading supplier of biometrics ... has resigned, effective March 3, 2017, as co-Chief ... Treasurer of Aware citing a desire to retire.  Mr. ... the Board of Directors of Aware. ... co-President, General Counsel has been named Chief Executive Officer, ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... Pa. , March 29, 2017 Patients ... which is why CSL Behring awards Local Empowerment for ... rare disease patient groups. These groups tackle complex legislative ... heard on Capitol Hill and in statehouses across the ... the community-based grant was awarded to New England Hemophilia ...
(Date:3/29/2017)... , and HILDEN, Germany , March 29, 2017 /PRNewswire/ ... FRANKFURT PRIME STANDARD: QIA) today announced the U.S. launch of ... JAK2 assay), which was cleared by the U.S. Food and Drug Administration as ... allele in genomic DNA extracted from EDTA whole blood.* ... The ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ...
(Date:3/29/2017)... 29, 2017 /PRNewswire/ - Last year,s petition to the White ... only efforts active to generate awareness on the importance of new ... in the healthcare market place. ... Earlier this month Health Advance (OTC ... pharmaceutical and nutritional products, announced its endeavors on this generally ...
(Date:3/29/2017)... N.J. and PETACH TIKVAH, ...  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), ... technologies for neurodegenerative diseases, announced financial results ... "2016 was a highly successful ... important achievements and significant progress made on ...
Breaking Biology Technology:
Cached News: